Needham & Company Downgrades Sagent Pharmaceuticals (SGNT) to Hold; Valuation Call
Tweet Send to a Friend
Needham & Company downgraded Sagent Pharmaceuticals (NASDAQ: SGNT) from Buy to Hold.
Needham analyst says, "Shares’ stellar performance (+81%) since ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "Shares’ stellar performance (+81%) since ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
